Sign in
Emily Shutman

Emily Shutman

Research Analyst at Leerink Partners

New York, NY, US

Emily Shutman serves as a Research Associate at Leerink Partners, specializing in immuno-oncology and covering a diverse array of biotechnology companies such as Affimed N.V., Arcellx, Arcus Biosciences, Viridian Therapeutics, and Xenon Pharmaceuticals. Since joining Leerink Partners in 2022, Shutman has contributed to in-depth sector analysis, supporting lead analysts focused on innovative cancer therapies and related biopharmaceuticals. Her academic background includes an undergraduate degree from Haverford College, and she maintains active involvement in equity research for companies with market caps ranging from emerging biotechs to established sector leaders. Shutman’s credentials are consistent with industry standards for research roles, complemented by ongoing professional development in healthcare capital markets.

Emily Shutman's questions to Zymeworks (ZYME) leadership

Question · Q2 2025

Emily Shutman of Leerink Partners inquired about the upcoming HORIZON-GEA-01 trial readout, asking if PD-L1 status would be detailed in the top-line results and seeking clarity on the allocation of the remaining $500 million in regulatory milestones from partner Jazz Pharmaceuticals.

Answer

President, CEO & Chairman Kenneth Galbraith explained that the content of the top-line data release is at the discretion of partners Jazz and B1. He also stated that Zymeworks has not provided specific guidance on how the remaining $500 million in development milestones is allocated across various indications.

Ask follow-up questions

Fintool

Fintool can predict Zymeworks logo ZYME's earnings beat/miss a week before the call

Let Fintool AI Agent track Emily Shutman for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free